Toby Call, PhD

Toby Call, PhD is a co-founder at Hurdle. He has been instrumental in growing the first consumer epigenetic testing offerings, Hurdle’s larger suite of diagnostic testing as a service, and developing epigenetic biomarker discovery partnerships with big pharma. Toby has a PhD in Biochemistry from the University of Cambridge. He ran nationwide testing programs using the company’s world first CE-marked saliva COVID PCR test (highlighted by the UK government as a key innovation during the pandemic). Toby led the research and trial work behind the first saliva-based DNAm biomarker for systemic chronic inflammation and ageing (in collaboration with Bayer). Toby is passionate about democratising access to the latest biomarker technologies to ensure the healthy ageing of our societies.